Praxis Precision Medicines Lead ASM Seen Exceeding $4 Billion Peak Sales
Analyst Myles Minter projects Praxis Precision Medicines’ lead anti-seizure medication could achieve over $4 billion in peak annual global sales. This estimate surpasses Xenon Pharmaceuticals’ $2.6 billion forecast and exceeds Rapport Therapeutics’ $2 billion peak sales projection for its lead ASM.
1. Analyst Sales Estimate
Myles Minter of William Blair forecasts that Praxis Precision Medicines’ lead anti-seizure medication could generate more than $4 billion in annual peak sales, reflecting strong commercial potential for their potassium channel modulator.
2. Competitive Landscape
This projection positions Praxis ahead of Xenon Pharmaceuticals’ $2.6 billion peak sales estimate for azetukalner and above Rapport Therapeutics’ $2 billion forecast, highlighting intense competition in the epilepsy treatment market.